Product Releases
Single-Donor Seroconversion Panels for Hepatitis B, HIV
Thu, 2024-04-04 12:20
LISTED UNDER:
SeraCare Life Sciences has launched three new seroconversion panels that provide patient samples for Hepatitis B and HIV, expanding its existing line of seroconversion panels focusing on infectious disease. The new panels have been tested on market-leading assays. Each panel represents a single donor and demonstrates how that donor’s blood converts in the presence of the disease during the sample collection period, presenting a challenge to the assay. Each product’s data sheet provides a graphical depiction of the donor’s seroconversion, along with comparative data that enables customers to review their test results against the results of other industry assays.
- HBV Seroconversion Panel (PHM938) comprises six undiluted plasma samples from a single donor drawn over a six-day period and is HBV DNA positive from the first bleed.
- HBV Seroconversion Panel (PHM939) provides five undiluted plasma samples from a single donor drawn over a 21-day period and is also HBV DNA positive from the first bleed. These panels allow for challenging members for HBsAg assays and HBeAg assays, delivering results for both rapid and qualitative HBsAg methods.
- HIV-1 Seroconversion Panel (PRB978) provides seven undiluted plasma samples from a single donor and is designed to challenge HIV RNA positive members on traditional antibody methods.
Designed to help maintain high standards for assay development, regulatory compliance and method development, the line of seroconversion panels includes options for HIV, Hepatitis A, Hepatitis B, Hepatitis C and West Nile Virus. These panels help diagnostics manufacturers and clinical labs evaluate, monitor and troubleshoot assay performance. The panels are derived from undiluted samples from single donors after their exposure to an infectious disease and subsequent immune response.
SeraCare Life Sciences Inc., 800-676-1881, www.seracare.com
